Abstracts

PHARMACOKINETICS AND SAFETY OF ADJUSTED DARUNAVIR/RITONAVIR WITH RIFAMPIN IN PLWH

Darunavir (DRV)/ritonavir(r) is better tolerated than lopinavir (LPV)/r and has a higher genetic barrier to resistance. Co-administration of DRV/r with rifampin (RIF), the key component of first-line TB treatment, is currently contraindicated as significant reductions in DRV exposures are expected; this has been a barrier to the use of DRV/r in resource-limited settings where TB…

INTRAHEPATIC HEPATITIS C KINETICS WITH DIRECT-ACTING ANTIVIRALS IN HIV COINFECTION

Direct-acting antivirals (DAA) target hepatitis C virus (HCV) proteins, dramatically improving treatment in HIV/HCV co-infection. The DAA effect in liver, however, is not well understood. We examined intrahepatic clearance of HCV.   A5335S, a substudy of trial A5329 (Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir, with Ribavirin) enrolled persons co-infected with HIV, suppressed HIV RNA on antiretrovirals, and chronic…